ERIC 2018 | Cellular therapies in CLL: from transplant to CAR T-cells?
Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses cellular therapies in chronic lymphocytic leukemia (CLL), starting with transplant and now moving towards CAR T-cells. Excitingly, treatment with ibrutinib has been shown to improve response rates to CAR T-cells in CLL; however, the track record of this novel therapy is of course shorter than that of stem cell transplantation. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
Get great new content delivered to your inboxSign up